Cybersecurity for robot-assisted surgery and telesurgery platforms.
Surgical robots are large, networked control systems running real-time software in an OR environment. Cyber faults can disrupt a procedure mid-case. We model the OR network, harden console-to-arm control paths, and run authenticated pen tests against vision, control, and service interfaces.
Surgical robots are networked, sensor-rich, and operate in cyber-physical real time. They live on hospital networks alongside imaging, navigation, and EHR systems - and rely on vendor remote-service tunnels that are often the riskiest interface in the product.
FDA reviewers and hospital biomed teams now expect segmentation diagrams, service-tunnel threat models, and forensic-readiness evidence as part of the cybersecurity package.
Typical clinical uses
Key data flows & integrations
Robotic systems often share VLANs with imaging and EHR - lateral movement from a compromised endpoint must be modeled.
Vendor remote-service tunnels need MFA, jump-host isolation, and full session logging.
Control messages between console and arms need integrity protection without breaking deterministic timing.
Public exploitation of surgical robots in clinical settings has not been disclosed, but the platform stack - networked controllers, vendor remote service, embedded Linux/Windows - has produced repeated advisories. Reviewers expect threat models that take that history seriously.
Historical incidents
Academic research on the Raven II open-source surgical robot demonstrated that an unprotected control channel between surgeon console and robot could be intercepted and modified, enabling motion-command tampering and denial-of-service against an in-progress procedure.
Bonaci et al., 'To Make a Robot Secure' (arXiv:1504.04339)
The 2019 URGENT/11 advisory affected a wide range of vendor controllers, programmers, and bedside systems - including platforms connected to surgical workflows. FDA directed manufacturers across categories to assess exposure to the VxWorks IPnet stack vulnerabilities.
FDA Safety Communication, Oct 2019CISA ICSMA-19-274-01
Multiple HHS HC3 and joint advisories have flagged vendor remote-service tunnels as a recurring entry point for ransomware and unauthorized access in healthcare environments. Surgical robot service tunnels are a frequent example in threat-modeling reviews.
HHS HC3 Threat Brief, Healthcare Sector Vendor Risk
Active threat scenarios
Robots sharing a VLAN with imaging or EHR endpoints are reachable from compromised endpoints elsewhere in the hospital.
Service tooling is a privileged client - a single compromised jump host can affect multiple deployed systems.
Without integrity protection that respects deterministic timing, a man-in-the-middle on the control plane can alter motion commands.
Trusting imaging or EHR feeds by default means a compromise upstream of the robot becomes a compromise of the procedure.
What FDA reviewers cite
Surgical robots are networked, sensor-rich, and operate in cyber-physical real time - latency-sensitive and high-consequence under any compromise.
Vendor-managed remote service is often the riskiest path in - it must be modeled, segmented, and logged like a production interface.
Hospitals can't take robots offline easily; secure update mechanisms have to be robust, fast, and roll-back-safe.
Imaging and EHR feeds are commonly trusted by default - your threat model must treat them as untrusted inputs.
Robots typically combine RTOS, embedded Linux, and Windows in one product - SBOM and patching strategy must cover all three.
What FDA scrutinizes
Vendor remote service is usually the highest-risk interface - reviewers want it modeled, segmented, MFA-enforced, and logged.
Motion-command tampering requires explicit safety + cyber analysis, including fail-safe behavior under signal loss.
Most robots combine RTOS, embedded Linux, and Windows in one product - SBOM and patching strategy must cover all three.
Standards & deliverables
Six deliverables FDA and notified bodies expect across MedTech, with the surgical robotics-specific wrinkle on each row. Use it as a scoping checklist before you brief vendors or your QA team.
| Deliverable | Status | Cadence | Standard / guidance | Surgical Robotics note |
|---|---|---|---|---|
| SBOM + VEX Machine-readable SBOM (CycloneDX/SPDX) plus VEX feed for every CVE that touches a listed component. |
Required | Premarket + monthly refresh | FDA Cybersecurity Guidance §V · CISA SBOM minimum elements | SBOM has to span RTOS, embedded Linux, and Windows components in one product - reviewers will check. |
| Postmarket monitoring Continuous CVE / advisory monitoring against the SBOM, with a documented triage and disclosure path. |
Required | Continuous (≤30-day triage) | FD&C Act §524B · FDA Postmarket Cybersecurity Guidance | Postmarket plan must address vendor remote-service tooling as an ongoing surface, not a one-time review. |
| Penetration test scope Black/grey-box testing across device, wireless interfaces, mobile apps, cloud APIs, and service tooling. |
Required | Premarket + on material change | AAMI TIR57 · FDA Premarket Cyber Guidance §VI.A.5 | Pen test scope: robot ↔ console, hospital LAN segmentation, vendor jump hosts, and DICOM/HL7 inputs. |
| Threat model STRIDE-per-interface threat model with documented mitigations and residual-risk acceptance. |
Required | Premarket, refreshed each design change | AAMI TIR57 · FDA Premarket Cyber Guidance §V.A | Treat imaging and EHR feeds as untrusted; surgical-instrument identity belongs in the model. |
| Secure update mechanism Signed firmware/software updates with rollback protection, integrity verification, and staged rollout. |
Required | Designed premarket, exercised lifecycle-long | FDA Cyber Guidance §IV · IEC 81001-5-1 | Updates must be fast, rollback-safe, and compatible with surgical-schedule constraints. |
| Coordinated Vulnerability Disclosure Public CVD policy, intake channel, and SLAs for triage, fix, and customer communication. |
Required | Continuous, lifecycle-long | ISO/IEC 29147 + 30111 · Section 524B(b)(2) | CVD program needs hospital-clinician intake plus a vendor-service-engineer reporting channel. |
Machine-readable SBOM (CycloneDX/SPDX) plus VEX feed for every CVE that touches a listed component.
Continuous CVE / advisory monitoring against the SBOM, with a documented triage and disclosure path.
Black/grey-box testing across device, wireless interfaces, mobile apps, cloud APIs, and service tooling.
STRIDE-per-interface threat model with documented mitigations and residual-risk acceptance.
Signed firmware/software updates with rollback protection, integrity verification, and staged rollout.
Public CVD policy, intake channel, and SLAs for triage, fix, and customer communication.
Yes - and it usually should be. We test against staging units, lab benches, vendor-provided digital twins, and instrumented sub-assemblies (console, vision tower, arm controller) so destructive or fault-injection testing never touches a system that could be used on a patient. On-site testing is reserved for hardware-specific interfaces (instrument identification, service ports, OR network integration) and is always coordinated with your safety, risk, and clinical engineering teams. The test plan documents which findings were exercised on real hardware vs. an emulated path so FDA reviewers can trace coverage back to the threat model.
We model the robot, console, vision tower, instrument tray, and any imaging, navigation, or EHR integrations as a sub-network with explicit trust boundaries. Each interface (DICOM, HL7, FHIR, vendor service VPN, USB service ports, BLE foot-pedal, etc.) is enumerated with its protocol, authentication mechanism, data sensitivity, and failure mode. We document segmentation assumptions the hospital is expected to enforce - VLAN isolation, firewall rules, and zero-trust posture - and call out residual risk where the design depends on hospital controls. This makes the threat model verifiable in the field instead of an abstract diagram.
Remote service is one of the most scrutinized cyber surfaces on a surgical robot because it is high-privilege, persistent, and often outside hospital change control. We require and validate MFA on the service account, jump-host isolation between the public internet and the device, full session recording with tamper-evident storage, least-privilege scoping (no general shell unless explicitly justified), and time-bounded access tokens. The end-to-end path is then pen-tested - including credential handling on the vendor side - and documented as a controlled interface in the SPDF and MDS2.
Yes, but with strict constraints aligned to IEC 60601-1 and your IEC 14971 risk file. We exercise control messages for integrity, replay, ordering, and timing on staging hardware only, never on a clinical system, and we coordinate every test with your software safety classification (typically Class C under IEC 62304). Findings that could plausibly affect patient safety are immediately escalated, and the report cross-references the affected hazard analysis entries so your risk and regulatory teams can update controls in lockstep.
Each third-party module is treated as a distinct SBOM component with its own trust boundary, vulnerability monitoring obligation, and integration test plan. We review the vendor's SBOM (SPDX or CycloneDX), the integration glue code, the data path between modules (especially DICOM and proprietary RPC), and the update mechanism for that component. Where vendor SBOMs are missing or thin, we generate one ourselves via binary analysis so your postmarket monitoring under section 524B has complete coverage.
The current expected baseline is the FDA 2026 final premarket cybersecurity guidance, AAMI SW96 (security risk management), AAMI TIR57 (security risk management - principles), IEC 62304 (software lifecycle, generally Class C), IEC 60601-1 plus applicable particulars (e.g., -2-77 for robotic surgery, -2-2 for HF surgical), and IEC 81001-5-1 for the secure software lifecycle. NIST SP 800-30 informs threat assessment methodology, and ISO 14971 ties the security risk file back to overall device risk management.
Surgical robots almost always combine an RTOS (control plane), embedded Linux (vision/navigation), and Windows (HMI/service) in a single product, so the SBOM and postmarket plan must cover all three. We produce a unified SBOM per build, in SPDX or CycloneDX, with VEX statements for known-not-affected CVEs, and we configure continuous monitoring against NVD, vendor advisories, and CISA KEV. The postmarket plan documents triage SLAs by severity and the path from a CVE to a controlled software change under your QMS.
Hospitals cannot take a robot offline on short notice, so secure update mechanisms must be robust, fast, atomic, and rollback-safe - and that has to be a premarket design decision, not a postmarket scramble. We document the update architecture (signed, staged, A/B partitioning, integrity-verified at boot), the staged rollout strategy across customer fleets, the rollback path, and the operational SLAs you commit to. This evidence appears in both the SPDF and the postmarket cybersecurity management plan FDA expects under section 524B.
Yes. DICOM and HL7/FHIR ingestion is fuzzed and authorization-tested - reviewers increasingly expect parser memory-safety evidence given historical CVEs in DICOM toolkits. Instrument identification (RFID, 1-Wire, proprietary tag) is exercised for spoofing, replay, and counterfeit-instrument acceptance, since accepting a non-genuine instrument is both a safety and a business-model issue. Findings are mapped back to the relevant threat-model entries and to the corresponding test cases in your software V&V.
A typical premarket package includes: a STRIDE-based threat model scoped to the robot ecosystem, an architecture and data-flow diagram set, a unified SBOM with VEX, a vulnerability and exploitability analysis, an authenticated penetration test report covering control plane, service interfaces, and integrated modules, the security risk management file aligned to AAMI SW96 and ISO 14971, MDS2, labeling/security documentation for hospital procurement, and a postmarket cybersecurity management plan. Every artifact cross-references the others so reviewers can trace any control from threat to test to label.
For a new 510(k) or De Novo robotic platform, end-to-end premarket cyber work generally runs 8-14 weeks depending on the number of integrated modules, availability of staging hardware, and prior cybersecurity maturity. Threat modeling and SBOM work front-loads in weeks 1-4, pen testing and exploitability analysis run in weeks 4-10, and the consolidated submission package and postmarket plan close in weeks 10-14. Clearance-guarantee scope and timeline are confirmed in writing before kickoff.
Network-segmented test plans, video/control plane assessment, and SBOM management for complex robotic platforms.
"The timeliness of this project exceeded my expectations - this was not my experience with other vendors. Blue Goat Cyber delivered a thorough, detailed report and complete testing faster than I anticipated, without compromising quality."
Cybersecurity for robot-assisted surgery and telesurgery platforms.
